Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: FGFBP2

Summary for FGFBP2

Gene information	Gene symbol	FGFBP2
	Ensembl ID	ENSG00000137441
	Entrez ID	83888
	Gene name	fibroblast growth factor binding protein 2
	Synonyms	KSP37
	Gene type	protein_coding
	UniProtAcc	Q9BYJ0

Top

Dataset with differentially expressed gene: FGFBP2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.649921	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.322428	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.27399	5.38e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.687769	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.479291	1.30e-05
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	-0.252059	2.45e-14
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.998676	2.97e-27
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.311005	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.540491	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.556804	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.371258	7.38e-26
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.378705	1.08e-18
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.981171	2.90e-23
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.976841	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.546395	4.89e-16
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	0.985972	7.08e-14
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.590317	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	NK cells	-0.550693	5.18e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.902818	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.46004	1.77e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-1.04951	9.81e-45
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.796762	9.49e-32
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.776921	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.518606	4.92e-28

Top

Expression of FGFBP2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to FGFBP2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating FGFBP2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
FGFBP2	hsa-miR-508-5p	87.4186	NM_031950
FGFBP2	hsa-miR-1288-5p	84.4198	NM_031950
FGFBP2	hsa-miR-454-5p	80.6839	NM_031950
FGFBP2	hsa-miR-668-3p	80.5376	NM_031950

Page: 1

Top

Motifs and transcription factors (TFs) regulating FGFBP2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
FGFBP2	transfac_pro__M05935	ZNF382 (directAnnotation).
FGFBP2	transfac_pro__M06248	ZNF91 (directAnnotation).
FGFBP2	metacluster_144.10	ZNF100 (directAnnotation).
FGFBP2	metacluster_21.4	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
FGFBP2	taipale_tf_pairs__HOXB2_TBX3_AGGTGTTAATKN_CAP	HOXB2; TBX3 (directAnnotation).
FGFBP2	transfac_pro__M07448	ZBED1 (directAnnotation).
FGFBP2	transfac_pro__M06071	ZNF814 (directAnnotation).
FGFBP2	tfdimers__MD00302	IRF7; IRF8 (directAnnotation).
FGFBP2	transfac_pro__M05403	ADNP2 (inferredBy_Orthology).
FGFBP2	taipale__Esrra_DBD_TTCAAGGTCAN_repr	ESRRA (inferredBy_Orthology).
FGFBP2	transfac_pro__M06897	ZNF789 (directAnnotation).
FGFBP2	transfac_pro__M05397	ZNF444 (directAnnotation).
FGFBP2	metacluster_131.3	ZNF436 (inferredBy_Orthology).
FGFBP2	transfac_pro__M05874	ZNF564 (directAnnotation).
FGFBP2	tfdimers__MD00039	GATA1; GATA2; GATA3; GATA4; GATA5; GATA6 (directAnnotation).
FGFBP2	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
FGFBP2	taipale_tf_pairs__TEAD4_DLX3_RCATTCCNNNYAATTA_CAP	DLX3; TEAD4 (directAnnotation).
FGFBP2	taipale_tf_pairs__ETV2_DRGX_RSCGGAWRYATTA_CAP_repr	DRGX; ETV2 (directAnnotation).
FGFBP2	taipale_tf_pairs__GCM1_CEBPB_MTRSGGGNNNNNTTRCGYAAN_CAP	CEBPB; GCM1 (directAnnotation).
FGFBP2	metacluster_168.17	ZNF417; ZNF587 (directAnnotation).
FGFBP2	metacluster_122.4	CDC5L; ZNF382 (directAnnotation).
FGFBP2	transfac_pro__M05379	ZNF740 (inferredBy_Orthology).
FGFBP2	taipale_tf_pairs__ELK1_FOXI1_WGTTKMCGGAWRTN_CAP	ELK1; FOXI1 (directAnnotation).
FGFBP2	transfac_pro__M05304	ZBTB5 (directAnnotation).
FGFBP2	taipale_tf_pairs__HOXB2_NHLH1_NYMATTANNNNNCAGCTGNN_CAP_repr	HOXB2; NHLH1 (directAnnotation).
FGFBP2	nitta__Ets98B_TTCCCC20NTA_KH_TKGCGGATGCN_m1_c3	SPDEF (inferredBy_Orthology).
FGFBP2	kznf__ZNF684_Imbeault2017_OM_RCADE	ZNF684 (directAnnotation).
FGFBP2	transfac_pro__M06045	ZNF729 (directAnnotation).
FGFBP2	transfac_pro__M06086	ZNF17 (directAnnotation).
FGFBP2	metacluster_156.2	ATF3; ATF4; ATF4; ATF4; ATF4; ATF4; ATF4; CEBPG; CEBPG; DDIT3; MYC (directAnnotation). ATF4; ATF4; ATF4; CEBPG; DDIT3 (inferredBy_Orthology).
FGFBP2	metacluster_22.14	BACH1 (inferredBy_Orthology).
FGFBP2	transfac_pro__M03874	HOXA9 (directAnnotation).
FGFBP2	tfdimers__MD00255	PAX7; PITX3 (directAnnotation).
FGFBP2	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
FGFBP2	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	ETV4; TEAD4 (directAnnotation).
FGFBP2	taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP	ETV2; FOXI1 (directAnnotation).
FGFBP2	metacluster_141.4	GLIS2 (directAnnotation).
FGFBP2	tfdimers__MD00377	PBX1 (directAnnotation).
FGFBP2	transfac_pro__M06232	ZNF234 (directAnnotation).
FGFBP2	kznf__ZNF764_Imbeault2017_RP_ChIP-seq	ZNF764 (directAnnotation).
FGFBP2	transfac_pro__M06660	ZNF670 (directAnnotation).
FGFBP2	transfac_pro__M06174	ZNF93 (directAnnotation).
FGFBP2	yetfasco__TBP-TFIIA-TFIIB_1330	GTF2B; TBPL2 (inferredBy_Orthology).
FGFBP2	transfac_pro__M06408	ZSCAN30 (directAnnotation).
FGFBP2	jaspar__MA0141.3	ESRRB (directAnnotation).
FGFBP2	transfac_pro__M05982	ZFP14 (directAnnotation).
FGFBP2	metacluster_8.2	CBFB; CBFB; CBFB; CBFB; CBFB; RUNX1; RUNX1; RUNX1; RUNX1; RUNX1; RUNX2; RUNX2; RUNX2; RUNX3; RUNX3; ZNF558; ZNF558 (directAnnotation). BCL11B; RUNX1; RUNX2 (inferredBy_Orthology).
FGFBP2	transfac_pro__M05299	NKX2-6 (directAnnotation).
FGFBP2	transfac_public__M00237	AHR; ARNT (directAnnotation).
FGFBP2	taipale_cyt_meth__POU2F2_NTAATNTATGCN_eDBD_repr	POU2F2 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."